Rock Springs Capital Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Rock Springs Capital Management’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-44,586	Closed	-$234K	–	112
2024 Q4	$234K	Hold	44,586	–	–	0.01%	105
2024 Q3	$638K	Hold	44,586	–	–	0.02%	105
2024 Q2	$722K	Hold	44,586	–	–	0.02%	109
2024 Q1	$4.51M	Hold	44,586	–	–	0.11%	94
2023 Q4	$1.05M	Hold	44,586	–	–	0.03%	100
2023 Q3	$901K	Hold	44,586	–	–	0.02%	109
2023 Q2	$1.16M	Hold	44,586	–	–	0.03%	114
2023 Q1	$927K	Hold	44,586	–	–	0.02%	115
2022 Q4	$910K	Sell	44,586 -10,843	-20%	-$204K	0.02%	114
2022 Q3	$1.53M	Buy	55,429 +14,719	+36%	+$423K	0.04%	116
2022 Q2	$1.07M	Hold	40,710	–	–	0.03%	125
2022 Q1	$3.26M	Buy	40,710 +250	+0.6%	+$30.9K	0.08%	118
2021 Q4	$8.25M	Buy	40,460 +445	+1%	+$111K	0.19%	99
2021 Q3	$12.9M	Buy	+40,015	New	+$11.7M	0.27%	93

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rock Springs Capital Management's VINC Position: Q1 2025 in Review

Rock Springs Capital Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 44,586 shares — an estimated $234K sold.

Rock Springs Capital Management first reported a position in VINC in Q3 2021 and held it in 14 quarters. The position peaked at $12.9M in Q3 2021. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

Rock Springs Capital Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Rock Springs Capital Management sold 44,586 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $234K.
Rock Springs Capital Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2021 and held it in 14 quarters.
Rock Springs Capital Management's Vincerx Pharma, Inc. Common Stock position peaked at $12.9M in Q3 2021.
14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Rock Springs Capital Management's 13F filing for Q1 2025, filed 15 May 2025.